10-Q: Absci Corporation Reports First Quarter 2025 Financial Results, Highlights Clinical Trial Progress

Absci Corporation's Q1 2025 results show increased revenue from partner programs and ongoing clinical development of ABS-101 for Inflammatory Bowel Disease.

Summary

• Absci Corporation reported a net loss of $26.3 million for the three months ended March 31, 2025, compared to a net loss of $22.0 million for the same period in 2024.
• Partner program revenue increased to $1.2 million, up from $0.9 million in the prior year, driven by the timing of project-based milestones.
• Research and development expenses rose by 34% to $16.4 million, primarily due to the advancement of drug creation programs.
• The company initiated dosing in a Phase 1 clinical trial for ABS-101, a potential treatment for Inflammatory Bowel Disease, with an interim clinical readout expected in the second half of 2025.
• Preclinical development is ongoing for ABS-201, a potential treatment for androgenic alopecia, with a potential regulatory filing anticipated in the first half of 2026.
• Absci's cash, cash equivalents, and short-term investments totaled $134.0 million as of March 31, 2025.
• The company expects current resources to fund operations for at least the next 12 months.
• A strategic collaboration with AMD aims to optimize AI drug creation, supported by a $20.0 million investment from AMD.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there's progress in clinical trials and revenue growth, the increased net loss and competitive landscape temper the overall outlook.

Positives

• Partner program revenue increased, indicating growing demand for Absci's Integrated Drug Creation platform.
• Initiation of a Phase 1 clinical trial for ABS-101 marks a significant milestone in the development of internally developed programs.
• Strategic collaboration with AMD provides financial support and technological synergies for AI drug creation.
• The company's cash position is expected to sustain operations for at least the next 12 months.

Negatives

• Net loss increased from $22.0 million to $26.3 million, reflecting higher operating expenses.
• Research and development expenses increased, indicating higher investment but also potentially higher risk.
• The company has an accumulated deficit of $535.9 million, highlighting its history of losses.

Risks

• The company's limited operating history and dependence on partnered programs create uncertainty in predicting future performance.
• Biologic drug development is inherently uncertain, and product candidates may not achieve regulatory approval or commercial success.
• The biopharmaceutical platform technology market is highly competitive, and Absci faces competition from companies with greater resources.
• The company relies on third parties for preclinical studies and clinical trials, which could lead to delays or unsuccessful programs.
• Disruptions to the operations of the FDA and other government agencies could negatively impact the business.

Future Outlook

Absci expects to continue incurring significant expenses as it develops its internally developed programs, engages in research and development efforts, executes its business development strategy, and attracts and retains qualified personnel. The company believes its current cash, cash equivalents, and short-term investments will be sufficient to meet its operating expenses, working capital, and capital expenditure needs over at least the next 12 months.

Management Comments

• The business model is focused on monetizing our Integrated Drug Creation platform by generating internally developed programs that are later partnered or out-licensed following certain value inflection points (anywhere from preclinical through clinical development) or by partnering with third parties who wish to leverage our Integrated Drug Creation platform for early discovery efforts in a variety of deal structures.
• Our evolving business model is underpinned by our Integrated Drug Creation platform which supports a strategic diversification of our program portfolio through internally developed programs, partnered drug creation programs and co-development programs.
• This strategic diversification allows us the potential to balance our program portfolio between internally developed programs for which we have more control and may provide more significant economic returns, and partnered programs which broaden our reach into therapeutic areas where our partner has established capabilities and expertise.
• Thus, the cornerstone of this business model evolution lies in the diversification of risk and potential return on investment.
• Our business model not only secures a focused set of therapeutic areas, but also gives us greater optionality, enhancing our ability to pivot and adapt as the programs progress.
• We believe we will grow and diversify our portfolio of programs through our model, ultimately driving innovation and delivering value for all stakeholders.

Industry Context

Absci operates in the competitive biopharmaceutical platform technology market, facing competition from companies developing AI capabilities for biologic drug design and those offering adjacent technologies. The company's success depends on its ability to differentiate its Integrated Drug Creation platform and secure partnerships with pharmaceutical and biotechnology companies.

Comparison to Industry Standards

• Absci's approach of using generative AI to design antibody therapeutics is comparable to companies like Generate Biomedicines and Xaira Therapeutics.
• The company faces competition from companies offering AI-enabled small molecule design, such as Recursion Pharmaceuticals, Relay Therapeutics, Isomorphic Labs Limited, and Schrodinger, Inc.
• In the field of developing antibody therapeutics targeting TL1A for the treatment of inflammatory bowel disease, Absci is competing with Merck, Roche/Roivant, Sanofi/Teva, Spyre, and Xencor.
• In the field of developing antibody therapeutics targeting PRLR for the treatment of androgenic alopecia, Absci is competing with Hope Medicines.

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings.
• Employees are subject to the company's ability to attract and retain talent.
• Customers (partners) benefit from the advancement of the Integrated Drug Creation platform.
• Suppliers are subject to the company's ability to maintain relationships and manage supply chains.
• Creditors are subject to the company's ability to meet its financial obligations.

Next Steps

• Continue clinical development of ABS-101 with an interim clinical readout expected in the second half of 2025.
• Advance preclinical development of ABS-201 with a potential regulatory filing anticipated in the first half of 2026.
• Continue to engage in discovery, research and development efforts and scale our activities to meet potential demand from both new and existing partners.
• Execute an effective business development strategy to drive adoption of our Integrated Drug Creation platform by new and existing partners and, as relevant, to identify partners for internally developed programs.
• Develop, acquire, in-license or otherwise obtain technologies that enable us to expand our Integrated Drug Creation platform capabilities.
• Attract, retain and motivate highly qualified personnel.

Key Dates

Keywords

Absci, Integrated Drug Creation platform, antibody therapeutics, generative AI, clinical trial, ABS-101, ABS-201, AMD, partner program revenue, research and development, financial results, biologics, biopharmaceutical